AU2011280031B2 - Synthesis and use of Kinase inhibitors - Google Patents
Synthesis and use of Kinase inhibitors Download PDFInfo
- Publication number
- AU2011280031B2 AU2011280031B2 AU2011280031A AU2011280031A AU2011280031B2 AU 2011280031 B2 AU2011280031 B2 AU 2011280031B2 AU 2011280031 A AU2011280031 A AU 2011280031A AU 2011280031 A AU2011280031 A AU 2011280031A AU 2011280031 B2 AU2011280031 B2 AU 2011280031B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- formula
- solvent
- free base
- hydrochloride salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35994210P | 2010-06-30 | 2010-06-30 | |
| US61/359,942 | 2010-06-30 | ||
| PCT/US2011/042169 WO2012012139A1 (en) | 2010-06-30 | 2011-06-28 | Synthesis and use of kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2011280031A1 AU2011280031A1 (en) | 2013-01-10 |
| AU2011280031B2 true AU2011280031B2 (en) | 2015-09-10 |
Family
ID=45497129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011280031A Ceased AU2011280031B2 (en) | 2010-06-30 | 2011-06-28 | Synthesis and use of Kinase inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9505719B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2588476A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5923499B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103168037A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011280031B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2803005A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX343894B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ604801A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012012139A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201300012B (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012110773A1 (en) | 2011-02-17 | 2012-08-23 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| DK2675794T3 (da) | 2011-02-17 | 2019-05-06 | Cancer Therapeutics Crc Pty Ltd | Selektive fak-inhibitorer |
| WO2019117813A1 (en) * | 2017-12-15 | 2019-06-20 | National University Of Singapore | Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis |
| WO2026086879A1 (zh) * | 2024-10-25 | 2026-04-30 | 应世生物科技(南京)有限公司 | Fak抑制剂 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008115369A2 (en) * | 2007-03-16 | 2008-09-25 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4656182A (en) * | 1983-12-06 | 1987-04-07 | Warner-Lambert Company | Substituted trans-1,2-diaminocyclohexyl amide compounds |
| US20040006005A1 (en) | 2002-07-02 | 2004-01-08 | Sanjay Bhanot | Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| BR0114814A (pt) | 2000-10-11 | 2005-01-25 | Cephalon Inc | Composições compreendendo composto de modafinila e seu uso |
| AR040456A1 (es) * | 2002-06-27 | 2005-04-06 | Bristol Myers Squibb Co | Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana |
| US20080119515A1 (en) | 2003-03-10 | 2008-05-22 | M Arshad Siddiqui | Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis |
| GT200500310A (es) | 2004-11-19 | 2006-06-19 | Compuestos organicos | |
| US7935711B2 (en) | 2005-02-18 | 2011-05-03 | Tibotec Pharmaceuticals Ltd. | HIV inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives |
| CA2626579A1 (en) | 2005-10-25 | 2007-05-03 | Abbott Laboratories | Formulation comprising a drug of low water solubility and method of use thereof |
| US20080193518A1 (en) * | 2006-04-28 | 2008-08-14 | Schering Corporation | Process for the precipitation and isolation of 6,6-Dimethyl-3-Aza Bicyclo [3.1.0] Hexane-Amide compounds by controlled precipitation and pharmaceutical formulations containing same |
| CN101495095B (zh) * | 2006-04-28 | 2013-05-29 | 默沙东公司 | 通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂 |
| BRPI0715423A2 (pt) | 2006-07-21 | 2013-07-02 | Novartis Ag | formulaÇÕes para Éteres de benzimidazolil piridila |
| WO2009100176A2 (en) | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| WO2009105498A1 (en) * | 2008-02-19 | 2009-08-27 | Smithkline Beecham Corporation | Anilinopyridines as inhibitors of fak |
| CN102124000B (zh) * | 2008-06-17 | 2014-09-17 | 阿斯利康(瑞典)有限公司 | 吡啶化合物 |
| EP2464642A4 (en) | 2009-08-12 | 2013-01-09 | Poniard Pharmaceuticals Inc | PROCESS FOR PROMOTING APOPTOSIS AND METASTASENHEMMUNG |
| WO2011133668A2 (en) | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
-
2011
- 2011-06-28 CN CN2011800421749A patent/CN103168037A/zh active Pending
- 2011-06-28 NZ NZ60480111A patent/NZ604801A/en not_active IP Right Cessation
- 2011-06-28 WO PCT/US2011/042169 patent/WO2012012139A1/en not_active Ceased
- 2011-06-28 AU AU2011280031A patent/AU2011280031B2/en not_active Ceased
- 2011-06-28 MX MX2012014986A patent/MX343894B/es active IP Right Grant
- 2011-06-28 JP JP2013518575A patent/JP5923499B2/ja not_active Expired - Fee Related
- 2011-06-28 CA CA2803005A patent/CA2803005A1/en not_active Abandoned
- 2011-06-28 EP EP11810100.5A patent/EP2588476A4/en not_active Withdrawn
-
2013
- 2013-01-02 ZA ZA2013/00012A patent/ZA201300012B/en unknown
- 2013-08-07 US US13/961,517 patent/US9505719B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008115369A2 (en) * | 2007-03-16 | 2008-09-25 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
Also Published As
| Publication number | Publication date |
|---|---|
| NZ604801A (en) | 2015-03-27 |
| JP5923499B2 (ja) | 2016-05-24 |
| ZA201300012B (en) | 2013-09-25 |
| MX2012014986A (es) | 2013-07-03 |
| MX343894B (es) | 2016-11-28 |
| US9505719B2 (en) | 2016-11-29 |
| CA2803005A1 (en) | 2012-01-26 |
| AU2011280031A1 (en) | 2013-01-10 |
| JP2013529687A (ja) | 2013-07-22 |
| US20140235635A1 (en) | 2014-08-21 |
| EP2588476A4 (en) | 2014-07-23 |
| CN103168037A (zh) | 2013-06-19 |
| EP2588476A1 (en) | 2013-05-08 |
| WO2012012139A1 (en) | 2012-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3087912A1 (en) | Prodrugs of ketamine, compositions and uses thereof | |
| CA3203285A1 (en) | Heteroaryl carboxamide compound | |
| CN104955811B (zh) | 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物 | |
| AU2023210960B2 (en) | Amide compound as potassium channel regulator, and preparation therefor and use thereof | |
| US20180148403A1 (en) | Fenfluramine compositions and methods of preparing the same | |
| AU2015406100B2 (en) | Novel annelated phenoxyacetamides | |
| CA2112081C (en) | Imidazole compounds, their preparation and use | |
| JP2000510833A (ja) | 抗―ウイルス性化合物群 | |
| JP2010024243A (ja) | 緑内障および近視を処置するためのベンゾ[g]キノリン誘導体 | |
| AU2011280031A1 (en) | Synthesis and use of Kinase inhibitors | |
| CN102076679A (zh) | 新颖的四甲基取代的哌啶衍生物及其作为单胺神经递质再摄取抑制剂的用途 | |
| WO2015113521A1 (zh) | 氘代喹唑啉酮化合物以及包含该化合物的药物组合物 | |
| AU2014335859B2 (en) | Chromene derivatives substituted by alkoxide as inhibitors of the TCR-Nck interaction | |
| KR20040101563A (ko) | 5-ht-2c 수용체 길항제로 유용한 인돌린 유도체를포함하는 약제 조성물 | |
| JPH09506885A (ja) | 5ht▲下1d▼(抗うつ作用)活性を有するインドール、インドリンおよびキノリン誘導体 | |
| KR20070007888A (ko) | 결정질 n-데스메틸클로자핀 | |
| KR20260006612A (ko) | 이미다졸 함유 화합물, 이의 유도체 및 이의 용도 | |
| KR20230088358A (ko) | 아미노 컴브리태스태틴(Amino combretastatin) 유도체 및 이의 응용 | |
| JP2002534421A (ja) | 1−フェニル−4−(1−[2−アリール]シクロプロピル)メチルピペラジン:ドーパミン受容体リガンド | |
| CN110049768A (zh) | 酚噻嗪衍生物及其使用方法 | |
| JP2000516615A (ja) | 薬学的に活性な化合物及びその使用方法 | |
| CN102216290A (zh) | 苯并咪唑衍生物及其用于调节gabaa受体复合物的用途 | |
| JP2007529553A (ja) | N−アリール−ピペラジン誘導体を調製する方法 | |
| JP2000514075A (ja) | ベンゾ[g]キノリン誘導体 | |
| KR20100100968A (ko) | 신규한 피페리딘-4-카복실산 페닐-알킬-아미드 유도체 및 모노아민 신경전달물질 재흡수 억제제로서의 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ LEI, YIXIONG; BEHRENS, CARL HENRY; LI, HUI-YIN AND SUN, CONNIE L. |
|
| PC1 | Assignment before grant (sect. 113) |
Owner name: VERASTEM, INC. Free format text: FORMER APPLICANT(S): PONIARD PHARMACEUTICALS, INC. |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ SYNTHESIS AND USE OF KINASE INHIBITORS |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ LEI, YIXIONG; BEHRENS, CARL HENRY; LI, HUI-YIN AND SUN, CONNIE L. |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |